Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives
Martin Nilsson(Lund University), Niklas Loman(Lund University), Monica Emmertz, Åke Borg(Lund University), Ulf Kristoffersson, Christof Winter(TUM Klinikum), Christer Larsson(Lund University), Lao H. Saal(Domos (Norway)), Martin Rehn(Skåne University Hospital), Yvonne Brandberg(Karolinska Institutet)
Cited by 6
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k